{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:39:27Z","timestamp":1792798767978,"version":"4.5.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cancer is a multifactorial disease and the second leading cause of death worldwide after cardiovascular disease. Initially, it was considered a genetic disease or gene expression disorder, but now it is regarded as a tumor microenvironment (TME) disease. The TME consists of cancer cells, endothelial cells, fibroblasts, and immune cells that interact with each other. These interactions support tumor growth by providing nutrients via altered metabolic mechanisms such as glutamine metabolism, aerobic glycolysis, and fatty acid metabolism. The by-products of these altered metabolic pathways interfere with the function of surrounding cells and thus lead to cancer progression. The role of metabolic crosstalk highlights the intricate relationship between the cancer cells and their TME. This review comprehensively analyzes recent studies to enhance understanding of the metabolic crosstalk in TME. It highlights how tumor-associated macrophages and fibroblasts reprogram lipid and glucose metabolism to create an immunosuppressive environment. This review also provides information about the role of hypoxia-induced HIF-1\u03b1 signaling in the promotion of lactate accumulation. This factor in turn ensures tumor cells\u2019 survival and makes them resistant to anti-cancer drugs. Further, we have discussed therapeutic approaches targeting TME, including use of PD-1, PD-L1 inhibitors, CAR-T cell therapy, and oncolytic viruses to improve patient outcomes. Besides this, clinical studies involving the estimation of lactate, GLUT1, and HIF-1\u03b1 levels may help to recognize high-risk patients and develop guidance for personalized metabolism-targeting therapies. In the long run, such studies can ultimately improve patient outcomes and thus reduce disease burden.<\/jats:p>","DOI":"10.1186\/s43046-025-00317-8","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T23:02:29Z","timestamp":1757890949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Role of tumor microenvironment in cancer promotion, development of drug resistance and cancer treatment"],"prefix":"10.1186","volume":"37","author":[{"given":"Duaa e","family":"Fathah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samina","family":"Ejaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"issue":"3","key":"317_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.21037\/jtd.2017.02.75","volume":"9","author":"H Nagai","year":"2017","unstructured":"Nagai H, Kim YH. Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis. 2017;9(3):448\u201351.","journal-title":"J Thorac Dis"},{"key":"317_CR2","unstructured":"Society AC. Cancer Statistics 2024 [cited January 2025] Available from: https:\/\/www.cancer.org\/research\/cancer-factsstatistics\/all-cancer-facts-figures\/2024-cancer-facts-figures.html."},{"key":"317_CR3","unstructured":"IARC. Cancer Statistics 2022 [cited January 2025] Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/586-pakistan-fact-sheet.pdf ."},{"issue":"2","key":"317_CR4","first-page":"67","volume":"4","author":"F Saletta","year":"2015","unstructured":"Saletta F, Dalla Pozza L, Byrne JA. Genetic causes of cancer predisposition in children and adolescents. Transl Pediatr. 2015;4(2):67\u201375.","journal-title":"Transl Pediatr"},{"key":"317_CR5","doi-asserted-by":"publisher","first-page":"205031212110343","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034370.","journal-title":"SAGE Open Med"},{"issue":"23","key":"317_CR6","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343.","journal-title":"Oncotarget"},{"key":"317_CR7","unstructured":"Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. Lancet. 2021;397(10272):387\u201397."},{"key":"317_CR8","doi-asserted-by":"publisher","first-page":"205031212110343","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034370.","journal-title":"SAGE Open Med"},{"key":"317_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1164535","author":"M Proietto","year":"2023","unstructured":"Proietto M, Crippa M, Damiani C, Pasquale V, Sacco E, Vanoni M, et al. Tumor heterogeneity: preclinical models, emerging technologies, and future applications. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1164535.","journal-title":"Front Oncol"},{"key":"317_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.545126","volume":"8","author":"AH Nwabo Kamdje","year":"2020","unstructured":"Nwabo Kamdje AH, Seke Etet PF, Simo Tagne R, Vecchio L, Lukong KE, Krampera M. Tumor microenvironment uses a reversible reprogramming of mesenchymal stromal cells to mediate pro-tumorigenic effects. Front Cell Dev Biol. 2020;8: 545126.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"317_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","volume":"18","author":"R Baghban","year":"2020","unstructured":"Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59.","journal-title":"Cell Commun Signal"},{"issue":"9","key":"317_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41423-023-01061-6","volume":"20","author":"M Bied","year":"2023","unstructured":"Bied M, Ho WW, Ginhoux F, Bl\u00e9riot C. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol. 2023;20(9):983\u201392.","journal-title":"Cell Mol Immunol"},{"issue":"14","key":"317_CR13","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.7150\/ijbs.25720","volume":"14","author":"S Guo","year":"2018","unstructured":"Guo S, Deng CX. Effect of stromal cells in tumor microenvironment on metastasis initiation. Int J Biol Sci. 2018;14(14):2083\u201393.","journal-title":"Int J Biol Sci"},{"issue":"16","key":"317_CR14","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135.","journal-title":"Curr Biol"},{"key":"317_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5698","author":"Q Wang","year":"2023","unstructured":"Wang Q, Shao X, Zhang Y, Zhu M, Wang FX, Mu J, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023. https:\/\/doi.org\/10.1002\/cam4.5698.","journal-title":"Cancer Med"},{"issue":"1","key":"317_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-017-0600-4","volume":"16","author":"PR Prasetyanti","year":"2017","unstructured":"Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017;16(1):41.","journal-title":"Mol Cancer"},{"issue":"4","key":"317_CR17","first-page":"315","volume":"37","author":"P Conti","year":"2007","unstructured":"Conti P, Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tet\u00e8 S, et al. Role of mast cells in tumor growth. Ann Clin Lab Sci. 2007;37(4):315\u201322.","journal-title":"Ann Clin Lab Sci"},{"issue":"10","key":"317_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1369\/0022155414545334","volume":"62","author":"EZ da Silva","year":"2014","unstructured":"da Silva EZ, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 2014;62(10):698\u2013738.","journal-title":"J Histochem Cytochem"},{"issue":"6","key":"317_CR19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/modpathol.3800094","volume":"17","author":"S Dabiri","year":"2004","unstructured":"Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, et al. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol. 2004;17(6):690\u20135.","journal-title":"Mod Pathol"},{"key":"317_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.addr.2017.04.010","volume":"114","author":"C Ngambenjawong","year":"2017","unstructured":"Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206\u201321.","journal-title":"Adv Drug Deliv Rev"},{"issue":"18","key":"317_CR21","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u201366.","journal-title":"Cancer Res"},{"key":"317_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03074","author":"JL Hope","year":"2020","unstructured":"Hope JL, Spantidea PI, Kiernan CH, Stairiker CJ, Rijsbergen LC, van Meurs M, et al. Microenvironment-dependent gradient of CTL exhaustion in the AE17sOVA murine mesothelioma tumor model. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2019.03074.","journal-title":"Front Immunol"},{"issue":"1","key":"317_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1042\/BST20160387","volume":"45","author":"B Erdogan","year":"2017","unstructured":"Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. 2017;45(1):229\u201336.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"317_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-019-0994-2","volume":"18","author":"ME Fiori","year":"2019","unstructured":"Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70.","journal-title":"Mol Cancer"},{"key":"317_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042142","author":"R El Sayed","year":"2021","unstructured":"El Sayed R, Haibe Y, Amhaz G, Bouferraa Y, Shamseddine A. Metabolic factors affecting tumor immunogenicity: what is happening at the cellular level? Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22042142.","journal-title":"Int J Mol Sci"},{"key":"317_CR26","doi-asserted-by":"crossref","unstructured":"Campos GM, Am\u00e9rico MF, Dos Santos Freitas A, Barroso FAL, da Cruz Ferraz Dutra J, Quaresma LS, et al. Lactococcus lactis as an interleukin delivery system for prophylaxis and treatment of inflammatory and autoimmune diseases. Probiotics Antimicrob Proteins. 2024;16(2):352\u201366.","DOI":"10.1007\/s12602-023-10041-1"},{"issue":"1","key":"317_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.21037\/apm-20-2229","volume":"10","author":"J An","year":"2021","unstructured":"An J, Gu Q, Cao L, Yang H, Deng P, Hu C, et al. Serum IL-6 as a vital predictor of severe lung cancer. Ann Palliat Med. 2021;10(1):202\u20139.","journal-title":"Ann Palliat Med"},{"issue":"S4","key":"317_CR28","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.53730\/ijhs.v6nS4.10577","volume":"6","author":"D Adhiatma","year":"2022","unstructured":"Adhiatma D, Ali I, Ghoib H. Interleukin-6 serum levels in metastatic breast cancer and non-metastatic breast cancer. Int J Health Sci. 2022;6(S4):3512\u201320.","journal-title":"Int J Health Sci"},{"key":"317_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030627","author":"AG Alotaibi","year":"2023","unstructured":"Alotaibi AG, Li JV, Gooderham NJ. Tumour necrosis factor-alpha (TNF-\u03b1)-induced metastatic phenotype in colorectal cancer epithelial cells: mechanistic support for the role of microRNA-21. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15030627.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"317_CR30","doi-asserted-by":"publisher","DOI":"10.5812\/ijcm-124107","volume":"15","author":"A Aminizadeh","year":"2022","unstructured":"Aminizadeh A, Jarahi L, Khorami MB, Mohseni S, Bahrami A, Hosseini S, et al. Assessment of I-CAM1, V-CAM1, and E-selectin serum levels in patients with breast and pelvic cancer: a case control study. Int J Cancer Manag. 2022;15(11): e124107.","journal-title":"Int J Cancer Manag"},{"issue":"2","key":"317_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-023-03461-x","volume":"13","author":"M Venkataswamy","year":"2023","unstructured":"Venkataswamy M, Karunakaran RS, Islam MS, Meriga B. Capparis zeylanica L. root extract promotes apoptosis and cell cycle arrest, inhibits epithelial-to-mesenchymal transition and triggers E-cadherin expression in breast cancer cell lines. 3 Biotech. 2023;13(2): 41.","journal-title":"3 Biotech"},{"issue":"10","key":"317_CR32","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1210\/me.2004-0342","volume":"19","author":"P Reddy","year":"2005","unstructured":"Reddy P, Liu L, Ren C, Lindgren P, Boman K, Shen Y, et al. Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Mol Endocrinol. 2005;19(10):2564\u201378.","journal-title":"Mol Endocrinol"},{"key":"317_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1068469","author":"J Jiang","year":"2023","unstructured":"Jiang J, Li A, Lai X, Zhang H, Wang C, Wang H, et al. Correlation between metabolite of prostaglandin E2 and the incidence of colorectal adenomas. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1068469.","journal-title":"Front Oncol"},{"issue":"8","key":"317_CR34","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3390\/antiox12081533","volume":"12","author":"C-K Shen","year":"2023","unstructured":"Shen C-K, Huang B-R, Charoensaensuk V, Yang L-Y, Tsai C-F, Liu Y-S, et al. Bradykinin B1 receptor affects tumor-associated macrophage activity and glioblastoma progression. Antioxidants. 2023;12(8):1533.","journal-title":"Antioxidants"},{"issue":"3","key":"317_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.it.2023.01.004","volume":"44","author":"JB Burkett","year":"2023","unstructured":"Burkett JB, Doran AC, Gannon M. Harnessing prostaglandin E(2) signaling to ameliorate autoimmunity. Trends Immunol. 2023;44(3):162\u201371.","journal-title":"Trends Immunol"},{"issue":"10","key":"317_CR36","doi-asserted-by":"publisher","first-page":"9915","DOI":"10.1007\/s11033-022-07539-2","volume":"49","author":"DAB Rex","year":"2022","unstructured":"Rex DAB, Vaid N, Deepak K, Dagamajalu S, Prasad TSK. A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases. Mol Biol Rep. 2022;49(10):9915\u201327.","journal-title":"Mol Biol Rep"},{"key":"317_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2022.114889","volume":"220","author":"M Dadmehr","year":"2023","unstructured":"Dadmehr M, Mortezaei M, Korouzhdehi B. Dual mode fluorometric and colorimetric detection of matrix metalloproteinase MMP-9 as a cancer biomarker based on AuNPs@gelatin\/AuNCs nanocomposite. Biosens Bioelectron. 2023;220: 114889.","journal-title":"Biosens Bioelectron"},{"key":"317_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082380","author":"BM Kennedy","year":"2023","unstructured":"Kennedy BM, Harris RE. Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of colorectal cancer: correlated expression of EGFR, JAK STAT and Src genes, and a natural antisense transcript, RP11-C67.2.2. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15082380.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"317_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/cancers15020403","volume":"15","author":"P Limsakul","year":"2023","unstructured":"Limsakul P, Choochuen P, Charupanit G, Charupanit K. Transcriptomic analysis of subtype-specific tyrosine kinases as triple negative breast cancer biomarkers. Cancers (Basel). 2023;15(2):403.","journal-title":"Cancers (Basel)"},{"key":"317_CR40","unstructured":"Lewis, T. and W.L. Stone, Biochemistry, Proteins Enzymes. Internet ed. StatPearls [Internet], ed. StatPearls. 2025, Treasure Island: StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC."},{"key":"317_CR41","doi-asserted-by":"publisher","unstructured":"Abdeen Radwan A, Abd-Elazeem Hefney NE, Mohammed Kholef EF, Elebidi A, Mahmoud H. Transforming growth factor \u0392 as a marker of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Rep Biochem Mol Biol. 2023;11(4):702\u20139. https:\/\/doi.org\/10.52547\/rbmb.11.4.702.","DOI":"10.52547\/rbmb.11.4.702"},{"key":"317_CR42","doi-asserted-by":"publisher","unstructured":"Trifanescu OG, Gales LN, Tanase BC, Marinescu SA, Trifanescu RA, Gruia IM, et al. Prognostic role of vascular endothelial growth factor and correlation with oxidative stress markers in locally advanced and metastatic ovarian cancer patients. Diagnostics. 2023;13(1):166. https:\/\/doi.org\/10.3390\/diagnostics13010166.","DOI":"10.3390\/diagnostics13010166"},{"key":"317_CR43","doi-asserted-by":"crossref","unstructured":"Adams J, Duffy K, Moore M, Yang J. Cancer immunotherapy\u2014an emerging field that bridges oncology and immunology research. In: J R, editor. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering: Elsevier; 2017.","DOI":"10.1016\/B978-0-12-409547-2.12400-X"},{"issue":"2","key":"317_CR44","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1177\/03915603221150965","volume":"90","author":"MM Sami","year":"2023","unstructured":"Sami MM, Sherief MH, El-Abaseri TB, El-Sakka AI, El-Serafi AT. Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: clinical implication and prognostic significance. Urologia Journal. 2023;90(2):248\u201360.","journal-title":"Urologia Journal"},{"issue":"10","key":"317_CR45","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s00262-023-03490-8","volume":"72","author":"Z Duan","year":"2023","unstructured":"Duan Z, Li Z, Wang Z, Chen C, Luo Y. Chimeric antigen receptor macrophages activated through TLR4 or IFN-\u03b3 receptors suppress breast cancer growth by targeting VEGFR2. Cancer Immunol Immunother. 2023;72(10):3243\u201357.","journal-title":"Cancer Immunol Immunother"},{"key":"317_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101791","volume":"83","author":"PK Jayaswamy","year":"2023","unstructured":"Jayaswamy PK, Vijaykrishnaraj M, Patil P, Alexander LM, Kellarai A, Shetty P. Implicative role of epidermal growth factor receptor and its associated signaling partners in the pathogenesis of Alzheimer\u2019s disease. Ageing Res Rev. 2023;83: 101791.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"317_CR47","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-019-1074-3","volume":"18","author":"F Xie","year":"2019","unstructured":"Xie F, Xu M, Lu J, Mao L, Wang S. The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol Cancer. 2019;18(1):146.","journal-title":"Mol Cancer"},{"issue":"14","key":"317_CR48","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.3390\/cancers14143331","volume":"14","author":"MN Hasan","year":"2022","unstructured":"Hasan MN, Capuk O, Patel SM, Sun D. The role of metabolic plasticity of tumor-associated macrophages in shaping the tumor microenvironment immunity. Cancers (Basel). 2022;14(14):3331.","journal-title":"Cancers (Basel)"},{"key":"317_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00239","volume":"10","author":"M Nazemi","year":"2020","unstructured":"Nazemi M, Rainero E. Cross-talk between the tumor microenvironment, extracellular matrix, and cell metabolism in cancer. Front Oncol. 2020;10: 239.","journal-title":"Front Oncol"},{"issue":"3","key":"317_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211\u20138.","journal-title":"Trends Biochem Sci"},{"key":"317_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.988295","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Li X, Wang L, Hong X, Yang J. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment. Front Endocrinol (Lausanne). 2022;13: 988295.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"317_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1113739","volume":"10","author":"Z Li","year":"2023","unstructured":"Li Z, Wang Q, Huang X, Yang M, Zhou S, Li Z, et al. Lactate in the tumor microenvironment: a rising star for targeted tumor therapy. Front Nutr. 2023;10: 1113739.","journal-title":"Front Nutr"},{"issue":"28","key":"317_CR53","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1038\/onc.2015.447","volume":"35","author":"L Jin","year":"2016","unstructured":"Jin L, Alesi GN, Kang S. Glutaminolysis as a target for cancer therapy. Oncogene. 2016;35(28):3619\u201325.","journal-title":"Oncogene"},{"key":"317_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-016-0769-9","author":"C Li","year":"2016","unstructured":"Li C, Zhang G, Zhao L, Ma Z, Chen H. Metabolic reprogramming in cancer cells: Glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer. World J Surg Oncol. 2016. https:\/\/doi.org\/10.1186\/s12957-016-0769-9.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"317_CR55","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/pcmedi\/pbz017","volume":"2","author":"M Chen","year":"2019","unstructured":"Chen M, Huang J. The expanded role of fatty acid metabolism in cancer: new aspects and targets. Precis Clin Med. 2019;2(3):183\u201391.","journal-title":"Precis Clin Med"},{"issue":"1","key":"317_CR56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122(1):4\u201322.","journal-title":"Br J Cancer"},{"issue":"1","key":"317_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mco2.27","volume":"2","author":"Y Fu","year":"2021","unstructured":"Fu Y, Zou T, Shen X, Nelson PJ, Li J, Wu C, et al. Lipid metabolism in cancer progression and therapeutic strategies. MedComm (2020). 2021;2(1):27\u201359.","journal-title":"MedComm (2020)."},{"issue":"5","key":"317_CR58","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"issue":"3","key":"317_CR59","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738.","journal-title":"Cancers (Basel)"},{"key":"317_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8: 86.","journal-title":"Front Oncol"},{"key":"317_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574271","volume":"11","author":"R Franzin","year":"2020","unstructured":"Franzin R, Netti GS, Spadaccino F, Porta C, Gesualdo L, Stallone G, et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand? Front Immunol. 2020;11: 574271.","journal-title":"Front Immunol"},{"key":"317_CR62","doi-asserted-by":"publisher","first-page":"1187850","DOI":"10.3389\/fimmu.2023.1187850","volume":"14","author":"CJ Sailer","year":"2023","unstructured":"Sailer CJ, Hong Y, Dahal A, Ryan AT, Mir S, Gerber SA, et al. PD-1Hi CAR-T cells provide superior protection against solid tumors. Front Immunol. 2023;14:1187850.","journal-title":"Front Immunol"},{"issue":"1","key":"317_CR63","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1186\/s12885-023-11536-4","volume":"23","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Mu W, Wang C, Zhuo Z, Xin Y, Li H, et al. Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in lymphoma patients. BMC Cancer. 2023;23(1):1019.","journal-title":"BMC Cancer"},{"key":"317_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5551","author":"S Abbasi","year":"2023","unstructured":"Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies. Cancer Med. 2023. https:\/\/doi.org\/10.1002\/cam4.5551.","journal-title":"Cancer Med"},{"key":"317_CR65","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250.","journal-title":"Front Immunol"},{"issue":"1","key":"317_CR66","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ejh.14076","volume":"112","author":"AN Khan","year":"2024","unstructured":"Khan AN, Asija S, Pendhari J, Purwar R. CAR-T cell therapy in hematological malignancies: where are we now and where are we heading for? Eur J Haematol. 2024;112(1):6\u201318.","journal-title":"Eur J Haematol"},{"issue":"5","key":"317_CR67","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"key":"317_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041003","author":"V Wang","year":"2023","unstructured":"Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15041003.","journal-title":"Cancers (Basel)"},{"issue":"26","key":"317_CR69","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"317_CR70","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory Mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"8","key":"317_CR71","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"10254","key":"317_CR72","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"1","key":"317_CR73","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2189097","volume":"38","author":"AK El-Damasy","year":"2023","unstructured":"El-Damasy AK, Jin H, Park JW, Kim HJ, Khojah H, Seo SH, et al. Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity. J Enzyme Inhib Med Chem. 2023;38(1): 2189097.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"317_CR74","doi-asserted-by":"publisher","DOI":"10.2174\/0929867330666230519105900","author":"J Su","year":"2024","unstructured":"Su J, Fu C, Wang S, Chen X, Wang R, Shi H, et al. Screening and activity evaluation of novel BCR-ABL\/T315I tyrosine kinase inhibitors. Curr Med Chem. 2024. https:\/\/doi.org\/10.2174\/0929867330666230519105900.","journal-title":"Curr Med Chem"},{"issue":"11","key":"317_CR75","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s11864-023-01137-5","volume":"24","author":"M Stanowicka-Grada","year":"2023","unstructured":"Stanowicka-Grada M, Senkus E. Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer. Curr Treat Options Oncol. 2023;24(11):1633\u201350.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"317_CR76","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","volume":"13","author":"SM Larson","year":"2023","unstructured":"Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, et al. CD19\/CD20 bispecific chimeric antigen receptor (CAR) in na\u00efve\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma. Cancer Discov. 2023;13(3):580\u201397.","journal-title":"Cancer Discov"},{"key":"317_CR77","doi-asserted-by":"crossref","unstructured":"Sharon S, Daher-Ghanem N, Zaid D, Gough MJ, Kravchenko-Balasha N. The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer. Frontiers in Oral Health. 2023;4.","DOI":"10.3389\/froh.2023.1180869"},{"key":"317_CR78","doi-asserted-by":"publisher","first-page":"175883592311860","DOI":"10.1177\/17588359231186027","volume":"15","author":"FY Kreidieh","year":"2023","unstructured":"Kreidieh FY, Tawbi HA. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. Ther Adv Med Oncol. 2023;15:17588359231186028.","journal-title":"Ther Adv Med Oncol"},{"key":"317_CR79","doi-asserted-by":"crossref","unstructured":"Di Giacomo AM, Lahn M, Eggermont AM, Fox B, Ibrahim R, Sharma P, et al. The future of targeting cytotoxic T-lymphocyte-associated protein-4: is there a role? European Journal of Cancer. 2023:113501.","DOI":"10.1016\/j.ejca.2023.113501"},{"key":"317_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101887","volume":"41","author":"M Yan","year":"2024","unstructured":"Yan M, Yang R, Li Q, Wang C, Chen J, Wu Z, et al. Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer. Transl Oncol. 2024;41: 101887.","journal-title":"Transl Oncol"},{"key":"317_CR81","doi-asserted-by":"crossref","unstructured":"Zhao T, Zhang T, Zhang Y, Zhou B, Lu X. Paclitaxel resistance modulated by the interaction between TRPS1 and AF178030. 2 in triple\u2010negative breast cancer. Evidence\u2010Based Complementary and Alternative Medicine. 2022;2022(1):6019975.","DOI":"10.1155\/2022\/6019975"},{"key":"317_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110723","volume":"108","author":"A Mandapati","year":"2023","unstructured":"Mandapati A, Ning Z, Baharani A, Lukong KE. BRK confers tamoxifen-resistance in breast cancer via regulation of tyrosine phosphorylation of CDK1. Cell Signal. 2023;108: 110723.","journal-title":"Cell Signal"},{"issue":"1","key":"317_CR83","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.vaccine.2022.09.070","volume":"41","author":"J Kim","year":"2023","unstructured":"Kim J, Kim E-D, Shin H-S, Han SJ, Jamiyansharav M, Yoon SC, et al. Effectiveness and safety of injectable human papilloma virus vaccine administered as eyedrops. Vaccine. 2023;41(1):92\u2013100.","journal-title":"Vaccine"},{"issue":"21","key":"317_CR84","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.3390\/jcm13216537","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS. Next-generation immunotherapy: advancing clinical applications in cancer treatment. J Clin Med. 2024;13(21):6537.","journal-title":"J Clin Med"},{"issue":"22","key":"317_CR85","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"10278","key":"317_CR86","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","volume":"397","author":"F Meric-Bernstam","year":"2021","unstructured":"Meric-Bernstam F, Larkin J, Tabernero J, Bonini C. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2021;397(10278):1010\u201322.","journal-title":"Lancet"},{"key":"317_CR87","doi-asserted-by":"crossref","unstructured":"Abaza A, Idris FS, Shaikh HA, Vahora I, Moparthi KP, Al Rushaidi MT, et al. Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immunotherapy: a promising breakthrough in cancer therapeutics. Cureus. 2023;15(9).","DOI":"10.7759\/cureus.44582"},{"issue":"5","key":"317_CR88","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. Car-t therapies in solid tumors: opportunities and challenges. Curr Oncol Rep. 2023;25(5):479\u201389.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"317_CR89","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"Z-L Liu","year":"2023","unstructured":"Liu Z-L, Chen H-H, Zheng L-L, Sun L-P, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"317_CR90","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.1038\/s41598-019-41924-5","volume":"9","author":"M Zhou","year":"2019","unstructured":"Zhou M, Hou J, Li Y, Mou S, Wang Z, Horch RE, et al. The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model. Sci Rep. 2019;9(1):6035.","journal-title":"Sci Rep"},{"issue":"4","key":"317_CR91","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJ, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933\u201359.","journal-title":"Cancer Discov"},{"issue":"4","key":"317_CR92","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/annonc\/mdw665","volume":"28","author":"R Bell","year":"2017","unstructured":"Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol. 2017;28(4):754\u201360.","journal-title":"Ann Oncol"},{"issue":"1","key":"317_CR93","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12964-022-00838-y","volume":"20","author":"MJ Ansari","year":"2022","unstructured":"Ansari MJ, Bokov D, Markov A, Jalil AT, Shalaby MN, Suksatan W, et al. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Commun Signal. 2022;20(1):49.","journal-title":"Cell Commun Signal"},{"issue":"11","key":"317_CR94","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.3390\/cancers12113299","volume":"12","author":"S Contarelli","year":"2020","unstructured":"Contarelli S, Fedele V, Melisi D. HOX genes family and cancer: a novel role for homeobox B9 in the resistance to anti-angiogenic therapies. Cancers (Basel). 2020;12(11):3299.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"317_CR95","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/annonc\/mdt573","volume":"25","author":"HA Yu","year":"2014","unstructured":"Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol. 2014;25(2):423\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"317_CR96","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, \u00d6sterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29\u201337.","journal-title":"Lancet Oncol"},{"issue":"6","key":"317_CR97","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1470-2045(15)70137-3","volume":"16","author":"HM Earl","year":"2015","unstructured":"Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(6):656\u201366.","journal-title":"Lancet Oncol"},{"issue":"13","key":"317_CR98","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344\u201354.","journal-title":"Lancet Oncol"},{"issue":"13","key":"317_CR99","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"317_CR100","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2012.48.5268","volume":"32","author":"MD Michaelson","year":"2014","unstructured":"Michaelson MD, Oudard S, Ou YC, Sengel\u00f8v L, Saad F, Houede N, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2014;32(2):76\u201382.","journal-title":"J Clin Oncol"},{"key":"317_CR101","first-page":"519","volume":"7","author":"G Lupo","year":"2016","unstructured":"Lupo G, Caporarello N, Olivieri M, Cristaldi M, Motta C, Bramanti V, et al. Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. Front Pharmacol. 2016;7:519.","journal-title":"Front Pharmacol"},{"key":"317_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100849","volume":"64","author":"M Huang","year":"2022","unstructured":"Huang M, Lin Y, Wang C, Deng L, Chen M, Assaraf YG, et al. New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects. Drug Resist Updat. 2022;64: 100849.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"317_CR103","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2217\/cns.12.36","volume":"2","author":"KV Lu","year":"2013","unstructured":"Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol. 2013;2(1):49\u201365.","journal-title":"CNS Oncol"},{"key":"317_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413422","author":"M Manetti","year":"2021","unstructured":"Manetti M. Molecular morphology and function of stromal cells. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222413422.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"317_CR105","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Shen M, Wu L, Yang H, Yao Y, Yang Q, et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 2023;14(9):587.","journal-title":"Cell Death Dis"},{"issue":"1","key":"317_CR106","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s42003-023-05733-x","volume":"7","author":"L Zhang","year":"2024","unstructured":"Zhang L, Cascio S, Mellors JW, Buckanovich RJ, Osmanbeyoglu HU. Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian cancer. Commun Biol. 2024;7(1):20.","journal-title":"Commun Biol"},{"issue":"1","key":"317_CR107","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13058-023-01760-y","volume":"26","author":"SJ Hachey","year":"2024","unstructured":"Hachey SJ, Hatch CJ, Gaebler D, Mocherla A, Nee K, Kessenbrock K, et al. Targeting tumor\u2013stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model. Breast Cancer Res. 2024;26(1):5.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"317_CR108","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12929-024-01099-2","volume":"32","author":"Z Cao","year":"2025","unstructured":"Cao Z, Quazi S, Arora S, Osellame LD, Burvenich IJ, Janes PW, et al. Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects. J Biomed Sci. 2025;32(1):7.","journal-title":"J Biomed Sci"},{"key":"317_CR109","doi-asserted-by":"crossref","unstructured":"Akce M, Shaib WL, Diab M, Alese OB, Wu C, Thomas S, et al. Phase Ib\/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer. American Society of Clinical Oncology; 2022.","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS626"},{"issue":"5","key":"317_CR110","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384.","journal-title":"Lancet Oncol"},{"issue":"1","key":"317_CR111","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13046-022-02524-w","volume":"41","author":"S Rizzolio","year":"2022","unstructured":"Rizzolio S, Giordano S, Corso S. The importance of being CAFs (in cancer resistance to targeted therapies). J Exp Clin Cancer Res. 2022;41(1):319.","journal-title":"J Exp Clin Cancer Res"},{"key":"317_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103980","author":"M Ajam-Hosseini","year":"2023","unstructured":"Ajam-Hosseini M, Akhoondi F, Doroudian M. Nano based-oncolytic viruses for cancer therapy. Crit Rev Oncol Hematol. 2023. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103980.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"317_CR113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1568009618666171129221503","volume":"18","author":"M Liang","year":"2018","unstructured":"Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18(2):171\u20136.","journal-title":"Curr Cancer Drug Targets"},{"issue":"9","key":"317_CR114","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642\u201362.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"317_CR115","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.3390\/pharmaceutics14091811","volume":"14","author":"Q Ji","year":"2022","unstructured":"Ji Q, Wu Y, Albers A, Fang M, Qian X. Strategies for advanced oncolytic virotherapy: current technology innovations and clinical approaches. Pharmaceutics. 2022;14(9):1811.","journal-title":"Pharmaceutics"},{"key":"317_CR116","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","volume":"17","author":"AL De Matos","year":"2020","unstructured":"De Matos AL, Franco LS, McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Molecular Therapy-Methods & Clinical Development. 2020;17:349\u201358.","journal-title":"Molecular Therapy-Methods & Clinical Development"},{"key":"317_CR117","doi-asserted-by":"publisher","first-page":"1308890","DOI":"10.3389\/fimmu.2023.1308890","volume":"14","author":"L Chen","year":"2023","unstructured":"Chen L, Zuo M, Zhou Q, Wang Y. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front Immunol. 2023;14:1308890.","journal-title":"Front Immunol"},{"issue":"10","key":"317_CR118","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","volume":"16","author":"M Mondal","year":"2020","unstructured":"Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020;16(10):2389\u2013402.","journal-title":"Hum Vaccin Immunother"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00317-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00317-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00317-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T23:02:34Z","timestamp":1757890954000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00317-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["317"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00317-8","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not include any studies with human participants and animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not include any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}